Trevena (TRVN) Reports Q4, Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Trevena Reports Fourth Quarter 2022 Results and Provides Business Update
March 30, 2023 7:00 AM EDTCompany announces initial topline OLINVYK data including GI and cognitive outcomes, and length of stay data from ~200 patient real-world clinical outcomes study
TRV045, a novel S1P receptor modulator, continues to advance as a potential treatment for epilepsy, diabetic neuropathic pain and other CNS disorders, with two proof-of-concept studies expected to complete enrollment by mid-2023
Cash balance of $38.3 million at year end 2022
Company to host conference call today, March 30, 2023 at 8:00 a.m. ET
CHESTERBROOK, Pa., March 30, 2023 (GLOBE NEWSWIRE) -- Trevena,... More
